Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 5:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 340 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Estrogen Receptor Positive Tumor Clear all
Active, not recruiting Not applicable Interventional Results available

A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

NCT01824836
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, Musculoskeletal Complications, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
anastrozole
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Female only
Enrollment
1,046 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • East Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 2, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Results available

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer

NCT03078751
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Adjuvant endocrine therapy, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
33
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 2, 2026, 5:18 AM EDT
Completed Phase 1 Interventional

MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer

NCT01344031
View directory record Official record
Conditions
Estrogen Receptor Positive, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Akt Inhibitor MK2206, Anastrozole, Fulvestrant, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Oct 2, 2026, 5:18 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Everolimus Beyond Progression

NCT02269670
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
everolimus, anastrozole, letrozole, tamoxifen citrate, fulvestrant, megestrol acetate
Drug
Lead sponsor
Emory University
Other
Eligibility
19 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 2, 2026, 5:18 AM EDT
Completed Phase 2 Interventional

Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery

NCT02760030
View directory record Official record
Conditions
Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Fulvestrant, Laboratory Biomarker Analysis, Palbociclib, Questionnaire Administration, Aromatase Inhibitors
Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
65 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
3
States / cities
Edgewood, Kentucky • Cleveland, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 2, 2026, 5:18 AM EDT
Terminated Phase 1Phase 2 Interventional

PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer

NCT01697293
View directory record Official record
Conditions
Breast Adenocarcinoma, Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Therapeutic Conventional Surgery, Triciribine Phosphate
Drug · Other · Procedure
Lead sponsor
Prescient Therapeutics, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
2
States / cities
Tampa, Florida • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 2, 2026, 5:18 AM EDT
Recruiting Phase 1 Interventional

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

NCT07029399
View directory record Official record
Conditions
HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
Interventions
NKT5097 CDK2/CDK4 dual degrader, Fulvestrant, Letrozole
Drug
Lead sponsor
NiKang Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
18
States / cities
Duarte, California • La Jolla, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 2, 2026, 5:18 AM EDT
Completed Phase 1 Interventional

A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread

NCT04132817
View directory record Official record
Conditions
Breast Cancer
Interventions
Nivolumab, Ipilimumab, Nab-paclitaxel
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 2, 2026, 5:18 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

NCT05654623
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
ARV-471, Fulvestrant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
87
States / cities
Encinitas, California • Fountain Valley, California • Fresno, California + 69 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 2, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Results available

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

NCT02993159
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive
Interventions
Afimoxifene, Laboratory Biomarker Analysis, Placebo, Tamoxifen Citrate
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Chicago, Illinois • Edgewood, Kentucky • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 2, 2026, 5:18 AM EDT
Active, not recruiting Phase 3 Interventional

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

NCT01953588
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Recurrent Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
fulvestrant, anastrozole
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
1,473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
856
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 524 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 2, 2026, 5:18 AM EDT
Terminated Phase 1 Interventional

Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer

NCT03128619
View directory record Official record
Conditions
Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Postmenopausal, Progesterone Receptor Positive, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
Biopsy of Breast, Copanlisib, Laboratory Biomarker Analysis, Letrozole, Palbociclib, Pharmacological Study
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Oct 2, 2026, 5:18 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Endocrine Therapy Effects of Host Immunity in Early Stage Breast Cancer

NCT03719495
View directory record Official record
Conditions
Breast Cancer, Estrogen Receptor-positive Breast Cancer, Healthy
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 2, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Results available

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

NCT03321981
View directory record Official record
Conditions
Breast Cancer Metastatic
Interventions
Zenocutuzumab, Trastuzumab, Vinorelbine, Endocrine therapy
Drug
Lead sponsor
Merus B.V.
Industry
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Los Angeles, California • Kansas City, Kansas • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 2, 2026, 5:18 AM EDT
Terminated Phase 2 Interventional Results available

Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy

NCT00759642
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
lapatinib
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
3
States / cities
Kansas City, Kansas • Topeka, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Oct 2, 2026, 5:18 AM EDT
Terminated Phase 2 Interventional Results available

Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells

NCT03070002
View directory record Official record
Conditions
Breast Carcinoma Metastatic in the Bone, Circulating Tumor Cell Count, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Stage IV Breast Cancer
Interventions
Denosumab, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Chicago, Illinois • Lake Forest, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 2, 2026, 5:18 AM EDT
Active, not recruiting No phase listed Observational

Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy

NCT03281902
View directory record Official record
Conditions
Advanced Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Biopsy, Biospecimen Collection, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 2, 2026, 5:18 AM EDT
Completed No phase listed Observational

Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer

NCT00283608
View directory record Official record
Conditions
Breast Cancer
Interventions
Single nucleotide polymorphism (SNP), high performance liquid chromatography, measurements by DXA, questionnaire administration
Genetic · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
4
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2011 · Synced Oct 2, 2026, 5:18 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer

NCT03284957
View directory record Official record
Conditions
Breast Cancer
Interventions
Amcenestrant, Palbociclib, Alpelisib, Everolimus, Abemaciclib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
4
States / cities
Aurora, Colorado • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 2, 2026, 5:18 AM EDT
Recruiting Phase 1 Interventional

A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

NCT04872166
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Breast Cancer
Interventions
BTX-A51
Drug
Lead sponsor
Edgewood Oncology Inc.
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Lake Mary, Florida • Sarasota, Florida • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 2, 2026, 5:18 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

NCT05154487
View directory record Official record
Conditions
Endometroid Endometrial Cancer
Interventions
Alpelisib Pill, Fulvestrant injection
Drug
Lead sponsor
GOG Foundation
Network
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
21
States / cities
Duarte, California • Miami Beach, Florida • Orlando, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 2, 2026, 5:18 AM EDT
Terminated Phase 2 Interventional Results available

Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer

NCT00379197
View directory record Official record
Conditions
Breast Cancer
Interventions
naltrexone, PET scan
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 2, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Results available

Lapatinib and Bevacizumab for Metastatic Breast Cancer

NCT00444535
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
lapatinib, bevacizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
9
States / cities
Tucson, Arizona • San Francisco, California • Hollywood, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 2, 2026, 5:18 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer

NCT01101438
View directory record Official record
Conditions
Breast Cancer
Interventions
metformin hydrochloride, placebo
Drug · Other
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
18 Years to 74 Years
Enrollment
3,649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
280
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Scottsdale, Arizona + 213 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 2, 2026, 5:18 AM EDT